Oscar Health reported record first-half results and raised its full-year 2026 guidance, prompting analysts to lift earnings estimates and highlight a low PEG ratio of 0.6. The upgraded guidance projects revenue of US$18.7 billion to US$19.0 billion and earnings from operations of US$500 million to US$700 million, reflecting management's confidence in improved profitability. However, risks remain from potential regulatory changes, subsidy shifts, and rising morbidity that could pressure medical loss ratios. The company's long-term narrative targets US$23.8 billion revenue and US$998.5 million earnings by 2029, implying a fair value of US$24.20 per share, a 21% downside to the current price. Some analysts project even higher figures, but the stock's investment case hinges on sustained margin improvement amid policy uncertainty.
Oscar Health IncRecord first-half results and raised full-year guidance prompt analysts to lift estimates, highlighting low PEG ratio.
